Wall Street Zen Upgrades Compugen (NASDAQ:CGEN) to Buy

Compugen (NASDAQ:CGEN) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

CGEN has been the topic of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Compugen in a report on Wednesday, January 21st. HC Wainwright initiated coverage on Compugen in a research report on Wednesday, January 7th. They issued a “buy” rating and a $4.00 target price on the stock. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $4.00.

Compugen Stock Up 1.5%

Shares of CGEN stock opened at $2.08 on Friday. Compugen has a one year low of $1.13 and a one year high of $2.38. The stock has a 50-day moving average of $1.84 and a 200-day moving average of $1.67.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings data on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.55. Compugen had a return on equity of 55.68% and a net margin of 48.57%.The business had revenue of $67.33 million during the quarter, compared to analyst estimates of $14.30 million. As a group, research analysts expect that Compugen will post -0.03 EPS for the current year.

Hedge Funds Weigh In On Compugen

Several large investors have recently modified their holdings of CGEN. Bank Hapoalim BM acquired a new stake in shares of Compugen during the 4th quarter worth about $37,000. Security National Bank of Sioux City Iowa IA acquired a new position in Compugen in the 4th quarter valued at about $38,000. Franklin Resources Inc. acquired a new position in Compugen in the 2nd quarter valued at about $56,000. Osaic Holdings Inc. raised its holdings in Compugen by 346.0% in the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 34,045 shares during the period. Finally, WINTON GROUP Ltd bought a new position in Compugen in the 4th quarter valued at about $84,000. 12.22% of the stock is owned by institutional investors.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.